"With our cloud-based solutions, we are on track to enhance patient outcomes significantly while reducing costs for healthcare systems around the world."
— CEO ResMed Inc
03Detailed Report
0KW4.L
ResMed Inc
Period
Q3 2024
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 28, 2026
Swipe to view all report sections
Executive Summary
ResMed Inc reported a robust performance in its Q3 2024 results, highlighting significant growth in revenue and profitability. The total revenue surged by 7.17% year-over-year (YoY) to $1.20 billion, driven primarily by the growth in the Sleep and Respiratory Care segments. Notably, net income increased by 29.24% YoY to $300.5 million, representing an impressive earnings per share (EPS) of $2.04. The company continues to strengthen its position in the healthcare market with innovative products and strategic software applications, which have enhanced patient outcomes and engagement.
Moreover, management expressed optimism regarding future growth, bolstered by favorable market conditions and an expanding customer base. The company's focus on cloud-based monitoring solutions aligns well with the evolving healthcare landscape, suggesting a strong trajectory for continued success in upcoming quarters.
Key Performance Indicators
Revenue
Increasing
1.20B
QoQ: 2.94% | YoY: 7.17%
Gross Profit
Increasing
681.58M
56.94% margin
QoQ: 5.35% | YoY: 10.33%
Operating Income
Increasing
374.58M
QoQ: 36.17% | YoY: 24.58%
Net Income
Increasing
300.49M
QoQ: 43.91% | YoY: 29.24%
EPS
Increasing
2.04
QoQ: 43.66% | YoY: 29.11%
Revenue Trend
Margin Analysis
Financial Highlights
Financial Performance:
- Revenue: $1,196.98 million (YoY growth of 7.17%, QoQ growth of 2.94%)
- Gross Profit: $681.58 million (Gross Profit Margin: 56.94%)
- Operating Income: $374.58 million (Operating Margin: 31.29%, YoY growth of 24.58%, QoQ growth of 36.17%)
- Net Income: $300.49 million (Net Income Margin: 25.10%, YoY growth of 29.24%, QoQ growth of 43.91%)
- EPS: $2.04 (YoY growth of 29.11%, QoQ growth of 43.66%)
Balance Sheet Health:
- Total Assets: $6.81 billion
- Total Liabilities: $2.18 billion
- Total Stockholders’ Equity: $4.63 billion
- Debt-to-Equity Ratio: 0.252
Cash Flow Analysis:
- Operating Cash Flow: $402.03 million
- Free Cash Flow: $378.92 million
- Cash Share: $1.77
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
1.20B
7.17%
2.94%
Gross Profit
681.58M
10.33%
5.35%
Operating Income
374.58M
24.58%
36.17%
Net Income
300.49M
29.24%
43.91%
EPS
2.04
29.11%
43.66%
Key Financial Ratios
Gross Profit Margin
Good
56.90%
Gross profit margin is healthy and competitive within industry standards
Operating Profit Margin
Excellent
31.30%
Operating margin is exceptional, indicating strong pricing power and operational efficiency
Net Profit Margin
Excellent
25.10%
Net profit margin is exceptional, indicating strong pricing power and operational efficiency
Return on Assets
Fair
4.41%
Return on assets is acceptable but below top-tier companies
Return on Equity
Fair
6.49%
Return on equity is acceptable but below top-tier companies
Current Ratio
Strong
3.04
Current ratio indicates excellent liquidity and financial flexibility
Debt to Equity
Conservative
0.25
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Fair Value
23.15x
P/E ratio in line with market averages
Price to Book
High Premium
6.01x
Very high premium suggests asset-light business model or lofty expectations
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.